All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-07-15T10:31:18.000Z

FDA grants CLR 131 Fast Track designation for the treatment of patients with relapsed or refractory DLBCL

Jul 15, 2019
Share:

Bookmark this article

On 9 July 2019, CLR 131, an investigational small-molecule radio-therapeutic, was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)1. CLR 131 is a phospholipid drug conjugate that selectively kills cancer cells by delivering cytotoxic radiation.

The Fast Track designation was based on the positive results from a multicenter phase II clinical trial (NCT02952508) CLOVER-1, which is evaluating the efficacy and safety of CLR 131 in R/R B-cell hematologic cancers. The interim assessment of the trial showed the overall response rate of 33%2. The topline data report is expected later this year.

CLR 131 is also being evaluated in phase I studies in pediatric solid tumors and lymphoma, as well as multiple myeloma (MM)3. Earlier CLR 131 was granted Orphan Drug designation for the treatment of MM, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma, and osteosarcoma.

  1. Globe news wire online. Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma.  https://www.globenewswire.com/news-release/2019/07/09/1880139/0/en/Cellectar-Receives-FDA-Fast-Track-Designation-for-CLR-131-in-Diffuse-Large-B-Cell-Lymphoma.html. Published; July 09 2019, [Accessed July 10 2019]
  2. Cellectar online. Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients. https://www.cellectar.com/news-media/press-releases/detail/182/cellectar-reports-positive-phase-2-interim-data-for-clr-131. Published; July 18 2018, [Accessed July 11 2019]
  3. Multiple Myeloma Hub online. Top-line results from the phase II study of CLR 131 – CLOVER-1.https://multiplemyelomahub.com/medical-information/top-line-results-from-the-phase-ii-study-of-clr-131-clover-1. Published; February 28 2019, [Accessed July 11 2019]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox